HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Increasing US Product Prices More Broadly With Commodity Headwinds Still Strong

Executive Summary

P&G raises prices on 9 of its 10 US product categories, rolling out increases in grooming, skin care and oral care products now. High commodity costs prompted it to increase its outlook for headwinds of $2.1bn for its FY2022.

You may also be interested in...



P&G Widens Pricing Strategy To At Least 60% Of Products As Costs Soar

Procter & Gamble’s pricing strategy now impacts 10 of its US product categories, with action also being taken broadly in non-US markets. President and CEO Jon Moeller calls this pricing "at a different level" historically speaking, and warns there will be ‘bumps in the road." But P&G is confident in its long track record and raises full-year guidance accordingly.

Groomed For Sustainable Growth, P&G Positions Shaving Brands To Provide Marketplace Edge

In first presentation at P&G’s helm, Jon Moeller says firm was groomed under his predecessor to grow revenues and income by developing line extensions for daily-use products offered at premium prices and by simplifying its operations for efficiency from executive suites to local distribution channels.

P&G Among US Firms Asked To Explain How, Why Supply Chain Problems Cause Consumer Hardships

Procter & Gamble and Amazon are among nine companies FTC ordered to provide detailed information to help the agency identify causes behind ongoing supply chain disruptions. Chairwoman Khan says the information should “shed light on market conditions and business practices that may have worsened these disruptions.”

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151859

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel